A Multi-center Post-Market Surveillance Registry (E-SELECT)
Primary Purpose
Coronary Artery Disease
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
drug-eluting stent
Sponsored by

About this trial
This is an interventional treatment trial for Coronary Artery Disease
Eligibility Criteria
Inclusion Criteria:
- This registry will be limited to subjects who have received only the CYPHER SELECT™ Sirolimus-eluting Coronary Stent during the index procedure;
- Males and females;
Exclusion Criteria:
- None.
Sites / Locations
- Clinique La Tour
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
1
Arm Description
CYPHER SELECT™ Sirolimus-eluting Coronary Stent
Outcomes
Primary Outcome Measures
acute, sub-acute and late stent thrombosis; Major Adverse Cardiac Events (MACE)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00438919
Brief Title
A Multi-center Post-Market Surveillance Registry
Acronym
E-SELECT
Official Title
The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE
Study Type
Interventional
2. Study Status
Record Verification Date
December 2009
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cordis Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This multicenter, prospective, observational registry will evaluate the safety and performance of the CYPHER SELECT™ Sirolimus-eluting Coronary Stent, and of all future generation of commercially approved Cordis Sirolimus-eluting Stents (SES), in routine clinical practice. Its objective is to measure the incidence and identify the predictors of acute, sub-acute and late stent thrombosis and Major Adverse Cardiac Events (MACE). Additional analyses will be performed in patient sub-populations, such as diabetes, in-stent restenosis (ISR), acute myocardial infarction (AMI) and multivessel coronary disease.
Detailed Description
The data will be collected in consecutive subjects treated with commercially available product and following standard clinical practice. This registry will be limited to subjects who have received only the CYPHER SELECT™ Sirolimus-eluting Coronary Stent during the index procedure. While no inclusion or exclusion criteria have been specified, uniform, complete and accurate data will be collected peri-procedurally, during the index hospitalization, and during follow-up. All subjects should be treated according to the Instruction For Use (IFU) including conduct of the stenting procedure, application of antiplatelet medication and any other medical therapy should be provided according to local usual practice. Data collection (Electronic Data Capture), data management, statistical analyses, monitoring and core laboratory evaluations will be assigned to independent organizations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15000 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
CYPHER SELECT™ Sirolimus-eluting Coronary Stent
Intervention Type
Device
Intervention Name(s)
drug-eluting stent
Intervention Description
CYPHER SELECT™ Sirolimus-eluting Coronary Stent
Primary Outcome Measure Information:
Title
acute, sub-acute and late stent thrombosis; Major Adverse Cardiac Events (MACE)
Time Frame
1, 6, 12, 24 and 36 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
This registry will be limited to subjects who have received only the CYPHER SELECT™ Sirolimus-eluting Coronary Stent during the index procedure;
Males and females;
Exclusion Criteria:
None.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philip Urban, MD
Organizational Affiliation
Clinique La Tour
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinique La Tour
City
Meyrin
ZIP/Postal Code
1217
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
21435513
Citation
Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Dzavik V, Ellis S, Gao R, Holmes D, Jeong MH, Legrand V, Neumann FJ, Nyakern M, Spaulding C, Worthley S; e-SELECT Investigators. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol. 2011 Mar 29;57(13):1445-54. doi: 10.1016/j.jacc.2010.11.028.
Results Reference
derived
Learn more about this trial
A Multi-center Post-Market Surveillance Registry
We'll reach out to this number within 24 hrs